MetaCap

BioMarin Pharmaceutical (BMRN) vs Madrigal Pharmaceuticals (MDGL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioMarin Pharmaceutical (BMRN) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 10.5% versus a loss of 30.8%. Over five years, MDGL leads with a +362.0% price change compared with -31.0% for BMRN. BioMarin Pharmaceutical is the larger company by market cap ($11.70 billion vs $8.81 billion), about 1.3 times the size, while Madrigal Pharmaceuticals is growing revenue faster (+432.1% vs +12.9%).

On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (9.6x vs 36.5x for Madrigal Pharmaceuticals). BioMarin Pharmaceutical converts more of its revenue into profit, with a net margin of 10.8% versus -30.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMRN+10.46%MDGL-30.82%
+31%-1%-34%
Nov 21, 20251 yearNov 20, 2026
BMRN-33.96%MDGL+360.07%
+660%+292%-77%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMRN versus MDGL key metrics
MetricBMRNMDGL
Share price$60.41$379.10
Market cap$11.70B$8.81B
1-day change-1.64%-4.45%
YTD return+1.65%-34.90%
1-year return+10.46%-30.82%
5-year return-31.02%+361.98%
Forward P/E9.6036.52
EPS (TTM)$-0.10$-5.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.22B$958.40M
Revenue growth (YoY)+12.87%+432.05%
Net income (latest FY)$348.90M$-288.28M
Gross margin77.73%—
Operating margin12.71%-31.31%
Net margin10.83%-30.08%
52-week high$70.98$615.00
52-week low$49.26$353.54
Distance from 52-week high-14.89%-38.36%
Analyst consensusbuystrong_buy
Avg. price target upside+49.48%+81.69%
Average volume2.35M370.07K
Shares outstanding193.69M23.23M
Employees3,221915
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BMRN has outperformed MDGL by 41.3 percentage points over the past year.
  • BioMarin Pharmaceutical is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
  • Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +12.87%).

About BioMarin Pharmaceutical

BMRN stock →

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.

Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees

About Madrigal Pharmaceuticals

MDGL stock →

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees

BMRN vs MDGL FAQ

Which is bigger, BioMarin Pharmaceutical or Madrigal Pharmaceuticals?

BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $11.70B compared with $8.81B for Madrigal Pharmaceuticals (MDGL).

Which stock has performed better over the past year, BMRN or MDGL?

BMRN returned +10.46% over the past 12 months, compared with -30.82% for MDGL (price return, excluding dividends). Past performance does not predict future results.

Are BioMarin Pharmaceutical and Madrigal Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons